A
Andrea Marie Perrone
Researcher at Merck & Co.
Publications - 13
Citations - 2440
Andrea Marie Perrone is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Response Evaluation Criteria in Solid Tumors. The author has an hindex of 10, co-authored 13 publications receiving 1801 citations. Previous affiliations of Andrea Marie Perrone include United States Military Academy.
Papers
More filters
Journal ArticleDOI
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour,Jan Bogaerts,Andrea Marie Perrone,Robert Ford,Lawrence H. Schwartz,Lawrence H. Schwartz,Sumithra J. Mandrekar,Nan Lin,Saskia Litière,Janet Dancey,Alice P. Chen,F. Stephen Hodi,Patrick Therasse,Otto S. Hoekstra,Lalitha K. Shankar,Jedd D. Wolchok,Marcus Ballinger,Marcus Ballinger,Marcus Ballinger,Caroline Caramella,Elisabeth G.E. de Vries +20 more
TL;DR: This guideline describes a standard approach to solid tumour measurements and definitions for objective change in tumour size for use in trials in which an immunotherapy is used and defines the minimum datapoints required from future trials to facilitate the compilation of a data warehouse to later validate iRECIST.
Journal ArticleDOI
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi,Wen-Jen Hwu,Richard F. Kefford,Jeffrey S. Weber,Adil Daud,Omid Hamid,Amita Patnaik,Antoni Ribas,Caroline Robert,Tara C. Gangadhar,Anthony M. Joshua,Peter Hersey,Roxana S. Dronca,Richard W. Joseph,Darcy A. Hille,Dahai Xue,Xiaoyun Nicole Li,S. Peter Kang,Scot Ebbinghaus,Andrea Marie Perrone,Jedd D. Wolchok +20 more
TL;DR: Based on survival analysis, conventional RECIST might underestimate the benefit of pembrolizumab in approximately 15% of patients; modified criteria that permit treatment beyond initial progression per RECIST v1.1 might prevent premature cessation of treatment.
Journal ArticleDOI
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Richard W. Joseph,Jeroen Elassaiss-Schaap,Richard F. Kefford,Richard F. Kefford,Wen-Jen Hwu,Jedd D. Wolchok,Anthony M. Joshua,Antoni Ribas,F. Stephen Hodi,Omid Hamid,Caroline Robert,Adil Daud,Roxana S. Dronca,Peter Hersey,Jeffrey S. Weber,Amita Patnaik,Dinesh P. de Alwis,Andrea Marie Perrone,Jin Zhang,S. Peter Kang,Scot Ebbinghaus,Keaven M. Anderson,Tara C. Gangadhar +22 more
TL;DR: In this paper, the authors assess the association of baseline tumor size with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827).
Journal ArticleDOI
Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
Richard W. Joseph,Jeroen Elassaiss-Schaap,Jedd D. Wolchok,Anthony M. Joshua,Antoni Ribas,F. Stephen Hodi,Omid Hamid,Caroline Robert,Adil Daud,Wen-Jen Hwu,Richard F. Kefford,Peter Hersey,Jeffrey S. Weber,Amita Patnaik,Dinesh P. de Alwis,Andrea Marie Perrone,Soonmo Peter Kang,Scot Ebbinghaus,Keaven M. Anderson,Tara C. Gangadhar +19 more
TL;DR: baseline tumor size is explored as a prognostic factor in addition to standard prognostic variables for overall survival in pts with metastatic melanoma treated with MK-...
Journal ArticleDOI
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
F. Stephen Hodi,Antoni Ribas,Adil Daud,Omid Hamid,Caroline Robert,Richard F. Kefford,Wen-Jen Hwu,Tara C. Gangadhar,Anthony M. Joshua,Peter Hersey,Jeffrey S. Weber,Roxana S. Dronca,Andrea Marie Perrone,Linda Gammage,Darcy A. Hille,Dahai Xue,Soonmo Peter Kang,Patrick Chun,Scot Ebbinghaus,Jedd D. Wolchok +19 more
TL;DR: This data indicates that both objective response and prolonged disease stabilization can occur after an initial increase in tumor size and this data supports the idea that immunotherapies should be considered as a “last resort” treatment for cancer diagnosis.